Company Filing History:
Years Active: 2025
Title: The Innovations of Fengqi Cao
Introduction
Fengqi Cao is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of therapeutic antibodies. His work focuses on addressing diseases related to the PD-L1 protein, which plays a crucial role in cancer immunotherapy.
Latest Patents
Fengqi Cao holds a patent for an "Anti-PD-L1 antibody and use thereof." This patent includes an isolated antibody or antigen-binding fragment that specifically binds to the human CD-L1 protein. It also encompasses a nucleic acid molecule encoding the antibody, therapeutic compositions, and their application in treating PD-L1 related diseases, such as tumors that are PD-L1 positive. He has 1 patent to his name.
Career Highlights
Cao is associated with Beijing Sinotau Bio-pharmaceuticals Technology Co., Ltd., where he continues to innovate in the field of antibody therapies. His work has the potential to significantly impact cancer treatment and improve patient outcomes.
Collaborations
Fengqi Cao collaborates with notable colleagues, including Tong Zhou and Zhe Li, who contribute to his research and development efforts in biopharmaceuticals.
Conclusion
Fengqi Cao's innovative work in developing anti-PD-L1 antibodies showcases his commitment to advancing cancer therapies. His contributions are vital in the ongoing fight against cancer, and his patent reflects the potential for significant medical breakthroughs.